• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Which Medications Have the Lowest Risk of Side Effects?

Which Medications Have the Lowest Risk of Side Effects?

October 30, 2020
Pavan Madan, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Pavan Madan, MD. Dr. Madan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Solmi M et al, World Psychiatry 2020;19(2):214–232

Adverse effects are important considerations when choosing psychotropic medications, especially in children and adolescents. This study pooled available research to compare the safety profiles of various psychotropics used in the pediatric population. The authors screened thousands of studies of psychotropics for 78 possible adverse effects. The combined sample of these studies included roughly 337,000 children and adolescents: 120,000 on antidepressants, 66,000 on antipsychotics, 148,000 on ADHD meds, and 1,600 on mood stabilizers.

Among antidepressants, escitalopram and fluoxetine fared best, while venlafaxine was the worst owing to anorexia, abdominal pain, hypertension, and suicidality. Sertraline also performed poorly due to gastrointestinal issues, insomnia, and weight gain. Among antipsychotics, lurasidone was found to be the least problematic, with asenapine in second place. Olanzapine was the most problematic with a host of side effects including sedation, metabolic syndrome, and extrapyramidal side effects, with aripiprazole in second-last place.

Turning to ADHD medications, methylphenidate stood out to be the safest, although it came out only slightly ahead of lisdexamfetamine, while atomoxetine was the worst of the lot due to gastrointestinal issues and weight loss. Surprisingly, guanfacine also had significant issues such as reports of abdominal pain, sedation, and (notably) QT prolongation. Finally, among the mood stabilizers, lithium was the most well tolerated, while sodium valproate trailed the pack with significant adverse effects like weight gain, sedation, and cytopenia.

A quick tally of the safest available agents favors escitalopram and fluoxetine for depression, lurasidone for schizophrenia, methylphenidate for ADHD, and lithium for bipolar disorder.

CCPR’s Take
This study yielded some surprises and is worth a close read. While venlafaxine’s higher side effect profile was expected, we had not imagined sertraline to do so much worse than escitalopram and fluoxetine. Furthermore, we had, perhaps incorrectly, considered guanfacine and atomoxetine mild “starter” medications, even placebo-like, but here the stimulants stood out for their advantages in both safety and efficacy. Lastly, lithium and lurasidone deserve more consideration, despite having a narrow therapeutic range and insurance issues respectively.
Child Psychiatry
KEYWORDS antidepressants antipsychotics lithium mood_stabilizers psychotropic-medication side-effects stimulants
Pavan Madan, MD.

The Evidence Base for Polypharmacy in ADHD

More from this author
www.thecarlatreport.com
Issue Date: October 30, 2020
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Mood Disorders in Children and Adolescents, CCPR, Oct/Nov/Dec 2020
Note From the Editor-in-Chief
Our Role in Community Disasters
Duty to Warn? Debating Antidepressant Suicidality
Managing Video Gaming in Children and Teens
What Do We Do About Dyslexia?
Oral Contraceptive Users and Depressive Symptoms
Vitamin D for ADHD?
Which Medications Have the Lowest Risk of Side Effects?
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.